Hindustan Bio Sciences Ltd (HINDBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Hindustan Bio Sciences Ltd on NSE and BSE, with an AI summary of each filing.
Mr. Shailendra Vyas (Membership No. 77193) has resigned from position of Company Secretary and Compliance officer with effect from closer of business hours of 31-10-2026
Change in Management · 31 Oct 2026, 8:04 pm
Hindustan Bio Sciences Q2 Results and Key Executive Resignation Hindustan Bio Sciences reported total revenue of Rs 85.04 lakhs for the quarter ended 30th Sep'26, compared to Rs 0.86 lakhs in the prior-year period. Net profit turned positive to Rs 31.04 lakhs, improving significantly from a net loss of Rs 5.85 lakhs in Q2 of the previous fiscal year, leading to a basic and diluted EPS of Rs 0.30. Separately, the board accepted the resignation of Mr. Shailendra Vyas as Company Secretary and Compliance Officer, effective from the closing hours of 31st Oct'26.
Approved the Un-Audited Standalone Financial Results of the company for the 2nd Quarter ended on 30th September 2026 along with the Limited Review Report and Secretary and Compliance ....
Outcome · 31 Oct 2026, 7:45 pm
Hindustan Bio Sciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 82.2 ■ EBITDA: 28.3 (Loss to Profit YoY | Loss to Profit QoQ) ■ EBITDA Margin (%): 34.4 ■ PAT: 31.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.30 (Loss to Profit YoY | Loss to Profit QoQ)
Hindustan Bio Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve Un-audited Financial ....
Intimation · 31 Oct 2026, 5:30 am
Hindustan Bio Sciences Schedules Board Meeting for Q2 Results Hindustan Bio Sciences Limited has notified BSE that its Board of Directors will meet on 31st Oct'26 at its registered office in Banjara Hills, Hyderabad. The board will primarily consider and approve the company's un-audited financial results for the second quarter ended 30th Sep'26, alongside other general business matters.
We would like to inform you that the 34th Annual General Meeting of the Company held on 30th September 2026 at the registered office of the company
Annual General Meeting · 30 Sept 2026, 10:20 pm
We would like to inform you that the 34th Annual General Meeting of the company held on 30th September 2026 at the register officer of the Company
Annual General Meeting · 30 Sept 2026, 10:14 pm
Proceedings of 34th Annual General Meeting Held on 30-09-2026
Annual General Meeting · 30 Sept 2026, 10:02 pm
With Reference to the subject cited please find the 34th Annual Report along with the intimation for the financial year 2025-26
Annual General Meeting · 04 Sept 2026, 12:00 am
Submission of 34th Annual Report including the notice of Annual General Meeting for the financial year 2025-26 under regulation 34 of SEBI (LODR), Regulation 2015
Others (Uncategorized) · 03 Sept 2026, 11:51 pm
Outcome of the Board Meeting held on 31-08-2026
Outcome · 31 Aug 2026, 10:12 pm
Hindustan Bio Sciences Approves Capital Reduction and Consolidation Scheme On 31 Aug'26, the board approved a capital reduction scheme to offset accumulated losses. Paid-up capital will be reduced from Rs. 2.05 cr to Rs. 92.26 lakh by cancelling 56.38 lakh equity shares. This will set off Rs. 1.13 cr against accumulated losses of Rs. 1.22 cr. Subsequently, the remaining shares (face value Rs. 2) will be consolidated into new shares of Rs. 10 face value. Shareholders will receive 9 new shares (Rs. 10 FV) for every 100 old shares (Rs. 2 FV). The scheme requires shareholder and NCLT approval.
Hindustan Bio Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 ,inter alia, to consider and approve Draft scheme of Reorganization/Rearrangement ....
Intimation · 27 Aug 2026, 3:06 am
Hindustan Bio Sciences Board to Consider Share Capital Reorganization Hindustan Bio Sciences (BSE: 532041) will hold a Board Meeting on 31 Aug '26 to consider a draft scheme for the reorganization and rearrangement of its share capital. The agenda also includes approving the revised notice for the 34th Annual General Meeting (AGM). In compliance with insider trading regulations, the trading window for designated persons will be closed from 27 Aug '26 until 48 hours after the meeting concludes. This corporate action is a key monitorable for potential changes in capital structure.
Approval of Un-audited Financial Results of the company for the first quarter ended 30 june 2026, along with Limited Review Report issued by statutory auditor
Financial Result · 31 Jul 2026, 9:40 pm
Hindustan Bio Sciences Q1FY27 Results Approved; Revenue Zero, Net Loss Widens Hindustan Bio Sciences reported a net loss of Rs. 11.29 lakhs for Q1FY27, widening from a profit of Rs. 1.40 lakhs in Q1FY26. Revenue from operations was nil, compared to Rs. 32.19 lakhs YoY. QoQ, the net loss narrowed slightly from Rs. 11.66 lakhs. Total expenses fell to Rs. 11.29 lakhs versus Rs. 32.11 lakhs YoY. Basic EPS stood at Rs. (0.11) against Rs. 0.01 YoY. The board also approved convening the 34th AGM on 30 Sep'26.
Outcome of the Board Meeting held on Friday, July 31 2026 as Required under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015
Outcome · 31 Jul 2026, 9:23 pm
Hindustan Bio Sciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 0.0 (-100.0% YoY) ■ EBITDA: -11.3 (Profit to Loss YoY | -0.3% QoQ) ■ EBITDA Margin (%): 0.0 (-43 bps YoY) ■ PAT: -11.3 (Profit to Loss YoY | +3.2% QoQ) ■ EPS (INR): -0.11 (Profit to Loss YoY | +0.0% QoQ)
Hindustan Bio Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve With reference to the ....
Intimation · 31 Jul 2026, 5:30 am
Hindustan Bio Sciences Sets Board Meeting for Q1 FY27 Results Hindustan Bio Sciences Ltd. (Scrip: 532041) announced its Board of Directors will meet on 31st Jul'26. The key agenda item is to consider and approve the un-audited financial results for the quarter ended 30th Jun'26. The meeting will be held at the company's registered office in Hyderabad.
Appointment of Internal Auditor for the year 2026-27
Change in Auditor · 31 May 2026, 12:39 am
Hindustan Biosciences Reports Q4 & FY26 Results, Re-appoints Internal Auditor Hindustan Biosciences reported a net loss of Rs 11.66 lakhs for Q4 FY26, a significant decline from a profit of Rs 10.79 lakhs in Q4 FY25. For the full year FY26, the company posted a net loss of Rs 7.89 lakhs versus a profit of Rs 10.08 lakhs in FY25. Revenue from operations for FY26 stood at Rs 73.71 lakhs, down from Rs 81.33 lakhs YoY. The Board also approved the re-appointment of Mr. GBK Viswanadham as the Internal Auditor for FY27. The statutory auditors issued an unmodified opinion.
Audited Financial Results for the Fourth Quarter and Financial year ended 31st March 2026
Financial Result · 31 May 2026, 12:36 am
Hindustan Biosciences Reports Q4 & FY26 Audited Financial Results Hindustan Biosciences reported a Q4 FY26 net loss of ₹11.66 lakhs, a significant decline from a profit of ₹10.79 lakhs YoY and ₹8.20 lakhs QoQ. Revenue from operations for the quarter was nil. For the full year FY26, the company posted a net loss of ₹7.89 lakhs, reversing a profit of ₹10.08 lakhs in FY25, while annual revenue fell 9.4% YoY to ₹73.71 lakhs. The Board approved the results on 30 May'26 and re-appointed Mr. GBK Viswanadham as Internal Auditor for FY27.
Financial Results for the Fourth Quarter and Financial Year ended 31st March 2026
Outcome · 31 May 2026, 12:20 am
Hindustan Bio Sciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -11.3 (Profit to Loss YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): 0.0 (-2534 bps YoY | -2003 bps QoQ) ■ PAT: -11.7 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.11 (Profit to Loss YoY | Profit to Loss QoQ)
Hindustan Bio Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Hindustan Bio Sciences ....
Intimation · 30 May 2026, 5:30 am
Hindustan Bio Sciences to Announce Q4 & FY26 Results on 30-May-26 Hindustan Bio Sciences Ltd (BSE: 532041) has scheduled a Board of Directors meeting for Saturday, 30-May-26, at 02:00 p.m. The primary agenda is to consider and approve the audited financial results for the quarter and year ended 31-Mar-26. The board will also review the corresponding audit report for the financial year.
Un-audited results for quarter ended 31-12-2025
Financial Result · 31 Jan 2026, 9:27 pm
Hindustan Biosciences Turns Profitable in Q3 FY26 on Strong Revenue Growth Hindustan Biosciences reported a net profit of ₹8.20 lakhs for Q3 FY26 (quarter ended 31-Dec-'25), a significant turnaround from a loss of ₹4.14 lakhs in Q3 FY25 and a loss of ₹5.85 lakhs in Q2 FY26. Total revenue for the quarter stood at ₹40.03 lakhs, compared to ₹0.86 lakhs in the preceding quarter. The strong QoQ revenue growth drove the profitability swing. Basic EPS for the quarter was ₹0.08, improving from a negative ₹0.04 in the year-ago period.
Outcome of Board Meeting
Outcome · 31 Jan 2026, 9:05 pm
Hindustan Biosciences Q3FY26 Results: Swings to Profitability QoQ and YoY Hindustan Biosciences reported a significant turnaround for Q3FY26, posting a net profit of ₹8.20 lakhs compared to a loss of ₹5.85 lakhs in Q2FY26 and a loss of ₹4.14 lakhs in Q3FY25. Revenue from operations for the quarter ended 31 Dec'25 stood at ₹38.25 lakhs. The company’s Board approved the un-audited financial results and Limited Review Report on 31 Jan'26. Basic EPS for the quarter was ₹0.08, a marked improvement from negative ₹0.06 QoQ and negative ₹0.04 YoY.
The Exchange has received the revised disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bosco Armando Menezes & Emily Bosco Menezes
Acquisition/ Disposal of Shares · 24 Jan 2026, 9:47 pm
Hindustan Bio Sciences: Acquirer Corrects Equity Capital Disclosure Bosco Armando Menezes filed a revised disclosure for Hindustan Bio Sciences, correcting an error in the company's equity share capital. The capital was corrected to ₹2,05,01,600 (1,02,50,800 shares at ₹2 each) from the previously stated ₹10,25,08,000 (at ₹10 each). On 22nd Jan'26, Bosco Menezes acquired 15,000 shares (0.14%) via the open market. This increases the combined holding of Bosco & Emily Menezes from 4.98% to 5.12% (525,000 shares). The acquirers are not part of the promoter group.
Intimation under SAST regulation 29(2)
Others (Uncategorized) · 23 Jan 2026, 11:51 pm
Hindustan Bio Sciences: Non-Promoter Shareholder Increases Stake via Open Market Purchase On 22-Jan'26, non-promoter acquirer Bosco Armando Menezes purchased 15,000 shares of Hindustan Bio Sciences (ISIN: INE597C01021) via an open market transaction. This acquisition increased his individual holding from 2.49% (2,55,000 shares) to 2.63% (2,70,000 shares). The combined holding of Bosco and Emily Menezes consequently rose from 4.98% to 5.12% of the company's total equity share capital. The company's equity capital remains at Rs. 2,05,01,600, consisting of 1,02,50,800 shares of Rs. 2 each.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bosco Armando Menezes & Emily Bosco Menezes
Acquisition/ Disposal of Shares · 22 Jan 2026, 9:09 pm
Non-Promoter Increases Stake in Hindustan Bio Sciences via Open Market Bosco Armando Menezes, a non-promoter, acquired 15,000 shares (0.14% stake) of Hindustan Bio Sciences via the open market on 22nd Jan'26. This purchase increased the combined holding of Bosco Menezes and Emily Menezes to 525,000 shares, representing 5.12% of the company's total voting capital, up from their previous holding of 4.98%. The company's total voting capital remains at 102,508,000 equity shares. The disclosure was made under SEBI's substantial acquisition regulations.
Hindustan Bio Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2026 ,inter alia, to consider and approve Intimation of Board ....
Intimation · 31 Jan 2026, 5:30 am
Hindustan Bio Sciences Sets Board Meeting for Q3 Results Hindustan Bio Sciences Limited (Scrip Code: 532041) announced a Board of Directors meeting scheduled for 31-Jan-26. The board will consider and approve the un-audited financial results for the quarter ended 31-Dec-25 (Q3FY26). The meeting will take place at the company's registered office in Hyderabad. This event is a key catalyst for the stock, as the forthcoming results will provide insight into the company's Q3 performance.
Special window for re-lodgment of transfer requests of physical shares pursuant to SEBI circular dated July 2, 2025
Others (Uncategorized) · 13 Jan 2026, 5:21 pm
Hindustan Biosciences Reports No Physical Share Transfer Requests in Special Window Hindustan Biosciences Ltd., through its Registrar and Transfer Agent (RTA), disclosed its status on physical share transfer requests. As of 06 Jan '26, under the special re-lodgement window mandated by a SEBI circular dated 02 Jul '25, the company received NIL requests. Consequently, NIL requests were processed, approved, or rejected during the period. This regulatory filing confirms no activity related to the physical-to-demat transfer requests under this specific SEBI provision for the reported month.
Special Window for re-lodgment of transfer requests of physical shares pursuant to SEBI circular dated July 2, 2025
Others (Uncategorized) · 17 Dec 2025, 8:24 pm
Hindustan Biosciences Physical Share Transfer Window Update Hindustan Biosciences Ltd. announced on 16th Dec'25 that it had opened a special window for re-lodgment of physical share transfer requests, per a SEBI circular dated 2nd Jul'25. The company's Registrar and Transfer Agent (RTA) confirmed that as of 5th Dec'25, it had received "NIL" requests for transfer. Consequently, no requests were processed, approved, or rejected during the period. The disclosure confirms zero activity under this specific compliance window.